Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered alone or in combination with Fostamatinib - Statin DDI

Exclusion Criteria

• - History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
• - History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IP as judged by the Investigator.
• - Any clinically significant abnormalities in clinical chemistry, hematology, or
• urinalysis results as judged by the Investigator.
• - Any clinically significant abnormal findings in vital signs as judged by the
• Investigator